New Zealand has the world's highest rates of serious illness caused by RSV, with 2000 children under five admitted to ...

ACIP is recommending that adults aged 50 to 59 years who are at increased risk for severe RSV disease receive a single dose of an RSV vaccine.

Vulnerable Australians aged 50-59 will be able to receive a vaccine for respiratory syncytial virus (RSV).

We recently published a list of Billionaire Ken Fisher’s 10 Healthcare Stock Picks with Massive Upside Potential. In this ...

Pfizer (NYSE:PFE) is a global pharmaceutical giant that has long been a cornerstone of medical innovation and today boasts a ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

Eligible infants aged up to two years who are vulnerable to severe RSV disease will be protected thanks to a dedicated catch-up program. The state-based program complements the Commonwealth maternal ...

This includes Abrysvo (Respiratory Syncytial Virus Vaccine), which in October 2024, the US Food and Drug Administration approved for the prevention of RSV-associated LRTD in adults aged 18 to 59 at ...

The updated recommendation lowers the recommended age for RSV vaccination from 60 to 50 years in adults who are at high risk. The US Centers for Disease Control and Prevention’s (CDC ...

With current CDC leadership waiting for Senate confirmation, the Advisory Committee's vaccination recommendations may be approved by Health Secretary Robert F. Kennedy Jr instead. HealthDay News ...

The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices (ACIP) has issued new separate recommendations supporting expanded use of Pfizer’s respiratory syncytial ...